1998
DOI: 10.1046/j.1365-3083.1998.00396.x
|View full text |Cite
|
Sign up to set email alerts
|

Reconstitution of Opsonizing Activity by Infusion of Mannan‐Binding Lectin (MBL) to MBL‐Deficient Humans

Abstract: Reconstitution ofOpsonizing Activity by Infusion of Mannan-Binding Lectin (MBL) to MBL-Deficient Humans. Scand J Immunol 1998;48:116-123 Mannan-binding lectin (MBL, previously named mannan-binding protein, MBP) is a serum collectin, which activates complement upon binding to microbial carbohydrates. This results in opsonization of the microorganisms as well as direct complement-mediated killing. Clinical evidence indicates that MBL has an important role in the innate immune defence against various pathogen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
80
1
3

Year Published

1999
1999
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 120 publications
(86 citation statements)
references
References 41 publications
2
80
1
3
Order By: Relevance
“…This phenomenon is consistent with findings of previous reports [31][32][33]. So far, only a single peak at a high-molecular-mass position was reported for purified serum MBL in humans [34][35][36][37] and other species [37][38][39]. It is simply thought that low-molecular-mass MBL (corresponding to peak 2) was overlooked because it did not bind to the carbohydrate resin, and only the fractions which did bind to the resin (corresponding to peak 1) were able to proceed to the next step in purification or identification.…”
Section: Discussionsupporting
confidence: 93%
“…This phenomenon is consistent with findings of previous reports [31][32][33]. So far, only a single peak at a high-molecular-mass position was reported for purified serum MBL in humans [34][35][36][37] and other species [37][38][39]. It is simply thought that low-molecular-mass MBL (corresponding to peak 2) was overlooked because it did not bind to the carbohydrate resin, and only the fractions which did bind to the resin (corresponding to peak 1) were able to proceed to the next step in purification or identification.…”
Section: Discussionsupporting
confidence: 93%
“…MBL replacement has been suggested as novel therapy in immunocompromised patients, 14 especially those at high risk of infection because of MBL insufficiency. Short-term administration of purified MBL from pooled donor plasma had a satisfactory safety profile and some observable efficacy in two MBL-deficient individuals 25 and a patient with severe CF. 26 If prospective studies confirm MBL2 polymorphisms as risk stratification factors in COPD, MBL replacement may provide targeted therapy for genetically susceptible, MBLdeficient COPD patients with frequent respiratory infections.…”
Section: Discussionmentioning
confidence: 99%
“…In fact, plasma-derived MBL has already been administered to a number of healthy volunteers 30 or selected patients 31 without adverse effects. It would be important to more clearly define subsets of MBL-deficient patients who are at increased risk of infection after chemotherapy and are thus treated effectively with MBL replacement therapy.…”
Section: Increased Risk Of Infection In Mbl Polymorphismmentioning
confidence: 99%